Clearside Biomedical CLSD has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
The OASIS study is a Phase 1/2a clinical dose-escalation trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection.
The study enrolled 8 patients in Cohort 3 and 8 patients in Cohort 4, all of whom received aflibercept at their first visit and a single dose of CLS-AX at their second visit one month later.
Thomas A. Ciulla, M.D., MBA, Chief Medical Officer, stated, “We look forward to providing more data on the potential benefits of combining targeted and compartmentalized suprachoroidal delivery via our SCS Microinjector® with the broad pan-VEGF attributes of axitinib. The completion of enrollment in OASIS is a critical milestone.”
The company is planing to share data readout from the full OASIS trial in the fourth quarter of this year.
The Age-related macular degeneration causes a progressive loss of central vision and is the most common cause of legal blindness in individuals over age 55.
Price Action: Clearside Biomedical shares are trading around 2 percent higher at $1.60 on Tuesday at the time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.